A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal transplant patients

2024-516577-76-00 Protocol RC20_0007 Phase I and Phase II (Integrated) - Bioequivalence study Ended

Start 28 Jun 2021 · End 14 Apr 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol RC20_0007

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Bioequivalence study
Status Ended
Participants planned 10
Countries 1
Sites 1

Kidney transplant

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]
Trial duration
28 Jun 2021 → 14 Apr 2025
Decision date (initial)
2024-08-14
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516577-76-00
EudraCT number
2020-000599-38
ClinicalTrials.gov
NCT04837092

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Kidney transplant

VersionLevelCodeTermSystem organ class
21.1 LLT 10051366 Kidney graft dysfunction 10022117

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
5 Allee De L Ile Gloriette, Cs 69301 Cs 69301
City
Nantes Cedex 1
Postcode
44093
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Coordonnateur

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Coordonnateur

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 10 1
Rest of world 0

Investigational sites

France

1 site · Ended
Centre Hospitalier Universitaire De Nantes
Nephrology, 38 Boulevard Jean Monnet, 44000, Nantes

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2021-06-28 2025-04-14

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-18 France Acceptable
2024-08-09
2024-08-14